Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
Surendra Pal Chaudhary,Stephanie Reyes,Matthew L Chase,Aparna Govindan,Lei Zhao,Jay Luther,Irun Bhan,Emily Bethea,Joseph W Franses,Elizabeth Paige Walsh,Leigh Anne Dageford,Shoko Kimura,Nahel Elias,Heidi Yeh,James Markman,Adel Bozorgzadeh,Kenneth Tanabe,Cristina Ferrone,Andrew X Zhu,Karin Andersson,Michael Thiim,Onofrio Antonio Catalano,Avinash Kambadakone,Parsia A Vagefi,Motaz Qadan,Daniel Pratt,Nikroo Hashemi,Kathleen E Corey,Joseph Misdraji,Lipika Goyal,Jeffrey W Clark
DOI: https://doi.org/10.1093/oncolo/oyac251
2023-02-10
The Oncologist
Abstract:Abstract Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the leading causes of hepatocellular carcinoma (HCC) worldwide. Limited data exist on surgical outcomes for NAFLD/NASH-related HCC compared with other HCC etiologies. We evaluated differences in clinicopathological characteristics and outcomes of patients undergoing surgical resection for NAFLD/NASH-associated HCC compared with other HCC etiologies. Methods Demographic, clinicopathological features, and survival outcomes of patients with surgically resected HCC were collected. NAFLD activity score (NAS) and fibrosis score were assessed by focused pathologic review in a subset of patients. Results Among 492 patients screened, 260 met eligibility (NAFLD/NASH [n = 110], and other etiologies [n = 150]). Median age at diagnosis was higher in the NAFLD/NASH HCC cohort compared with the other etiologies cohort (66.7 vs. 63.4 years, respectively, P = .005), with an increased percentage of female patients (36% vs. 18%, P = .001). NAFLD/NASH-related tumors were more commonly >5 cm (66.0% vs. 45%, P = .001). There were no significant differences in rates of lymphovascular or perineural invasion, histologic grade, or serum AFP levels. The NAFLD/NASH cohort had lower rates of background liver fibrosis, lower AST and ALT levels, and higher platelet counts (P < .01 for all). Median overall survival (OS) was numerically shorter in NAFLD/NASH vs other etiology groups, however, not statistically significant. Conclusions Patients with NAFLD/NASH-related HCC more commonly lacked liver fibrosis and presented with larger HCCs compared with patients with HCC from other etiologies. No differences were seen in rates of other high-risk features or survival. With the caveat of sample size and retrospective analysis, this supports a similar decision-making approach regarding surgical resection for NAFLD/NASH and other etiology-related HCCs.
oncology